Revolution Medicines director sells 10,143 shares

The director's reported sales were made under a Rule 10b5-1 plan adopted on June 23, 2026.

Rhea-AI Filing Summary

Revolution Medicines, Inc. director Elizabeth M. Anderson exercised options for 5,070 common shares on September 22, 2026, at an exercise price of $1.12 per share. She also sold 10,143 common shares that day. Four multi-trade sales had weighted-average prices of $191.8521, $192.5387, $193.4392 and $194.5887 per share; the 100-share sale was reported at $195.1500 per share. The transactions were made under a Rule 10b5-1 trading plan adopted June 23, 2026. Following the option transaction, 1,095 options remained.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 9 txns

Insider ANDERSON ELIZABETH M

Role Director

Sold 10,143 shs ($1.96M)

Approx. gross sale proceeds $1.96M

Approx. exercise cost $6K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F9	5,070	$0.00	$0.00
Exercise	Common Stock F1	5,070	$1.12	$6K
Sale	Common Stock F1, F2	910	$191.8521	$175K
Sale	Common Stock F1, F3	4,985	$192.5387	$960K
Sale	Common Stock F1, F4	2,648	$193.4392	$512K
Sale	Common Stock F1, F5	1,500	$194.5887	$292K
Sale	Common Stock F1, F6	100	$195.15	$20K
holding	Common Stock F7	--	--	--
holding	Common Stock F8	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 1,095 contracts (Direct); Common Stock — 4,333 shares (Direct); Common Stock — 41,990 shares (Indirect, See footnote)

Footnotes (9)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026.
2. F2. The transaction was executed in multiple trades at prices ranging from $191.65 to $191.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. The transaction was executed in multiple trades at prices ranging from $192.01 to $192.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
4. F4. The transaction was executed in multiple trades at prices ranging from $193.00 to $193.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
5. F5. The transaction was executed in multiple trades at prices ranging from $194.04 to $194.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
6. F6. Includes 1,191 restricted stock units.
7. F7. Held by David W. Anderson 1996 Irrevocable Trust.
8. F8. Held by Irrevocable Deed of Trust of David W. Anderson and Elizabeth M. Anderson.
9. F9. Fully vested.

Key Figures

Common shares acquired: 5,070 shares Option exercise price: $1.12 per share Sale 1: 910 shares at $191.8521 per share +5 more

8 metrics

Common shares acquired 5,070 shares Acquired through option exercise on September 22, 2026

Option exercise price $1.12 per share September 22, 2026

Sale 1 910 shares at $191.8521 per share Weighted-average sale price; trades ranged from $191.65 to $191.99 on September 22, 2026

Sale 2 4,985 shares at $192.5387 per share Weighted-average sale price; trades ranged from $192.01 to $192.99 on September 22, 2026

Sale 3 2,648 shares at $193.4392 per share Weighted-average sale price; trades ranged from $193.00 to $193.81 on September 22, 2026

Sale 4 1,500 shares at $194.5887 per share Weighted-average sale price; trades ranged from $194.04 to $194.96 on September 22, 2026

Sale 5 100 shares at $195.1500 per share Sale reported September 22, 2026

Options following transaction 1,095 options Reported following the September 22, 2026 option transaction

Key Terms

10b5-1 trading plan, weighted average sale price, Stock Option (Right to Buy), restricted stock units

4 terms

10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan"

A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.

weighted average sale price financial

"the price reported in Column 4 above reflects the weighted average sale price"

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

restricted stock units financial

"Includes 1,191 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RVMD shares did director Elizabeth M. Anderson sell, and at what prices?

Elizabeth M. Anderson, a Revolution Medicines director, reported sales of 10,143 common shares on September 22, 2026. Four multi-trade sales had weighted-average prices of $191.8521, $192.5387, $193.4392 and $194.5887 per share; the fifth sale was 100 shares at $195.1500 per share.

How many RVMD shares did Elizabeth M. Anderson acquire through option exercise?

She exercised options for 5,070 common shares at $1.12 per share on September 22, 2026. The derivative transaction reports 1,095 options following the transaction; the options were fully vested and have an expiration date of April 19, 2028.

Were Elizabeth M. Anderson's RVMD transactions made under a 10b5-1 plan?

Yes. Her reported transactions were made pursuant to a Rule 10b5-1 trading plan she adopted on June 23, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/24/2026 - 06:00 PM Accepted by SEC EDGAR 09/24/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ANDERSON ELIZABETH M

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2026		M(1)		5,070	A	$1.12	14,476	D
Common Stock	09/22/2026		S(1)		910	D	$191.8521(2)	13,566	D
Common Stock	09/22/2026		S(1)		4,985	D	$192.5387(3)	8,581	D
Common Stock	09/22/2026		S(1)		2,648	D	$193.4392(4)	5,933	D
Common Stock	09/22/2026		S(1)		1,500	D	$194.5887(5)	4,433	D
Common Stock	09/22/2026		S(1)		100	D	$195.15	4,333(6)	D
Common Stock								26,990	I	See footnote(7)
Common Stock								15,000	I	See footnote(8)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.12	09/22/2026		M(1)			5,070	(9)	04/19/2028	Common Stock	6,165	$0	1,095	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026.

2. The transaction was executed in multiple trades at prices ranging from $191.65 to $191.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The transaction was executed in multiple trades at prices ranging from $192.01 to $192.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. The transaction was executed in multiple trades at prices ranging from $193.00 to $193.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

5. The transaction was executed in multiple trades at prices ranging from $194.04 to $194.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

6. Includes 1,191 restricted stock units.

7. Held by David W. Anderson 1996 Irrevocable Trust.

8. Held by Irrevocable Deed of Trust of David W. Anderson and Elizabeth M. Anderson.

9. Fully vested.

	/s/ Jack Anders, as Attorney-in-fact for Elizabeth M. Anderson	09/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)